What changes in tigecycline dose occur with rifampin?

Interactions between Tigecycline and Rifampin

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including nosocomial pneumonia and complicated intra-abdominal infections [1]. Rifampin is a powerful antibiotic that is often used in combination with other medications to treat infections such as tuberculosis and pneumonia. However, when these two drugs are used together, interactions can occur that may require adjustments in tigecycline doses.

Increased Clearance of Tigecycline

Co-administration of rifampin with tigecycline can increase the clearance of tigecycline, leading to reduced serum concentrations of the drug [2]. Studies have shown that rifampin can induce the metabolism of tigecycline, which results in higher clearance and reduced efficacy of the antibiotic [3].

Recommendations for Tigecycline Dose Adjustment

When tigecycline is used concurrently with rifampin, the dosage of tigecycline should be increased. According to the package insert for tigecycline, the recommended dose of tigecycline should be 100 mg administered every 12 hours when used in combination with rifampin [4]. This adjustment is intended to maintain therapeutic levels of tigecycline in patients receiving concurrent rifampin therapy.

Monitoring for Efficacy and Safety

When adjusting the dose of tigecycline due to interactions with rifampin, it is essential to closely monitor the patient's response to therapy and adjust the dosage as necessary. Regular clinical assessments, laboratory tests, and pharmacokinetic monitoring can help ensure that tigecycline concentrations remain within the target range.

References

[1] DrugPatentWatch.com. (2023). Tigecycline - 2023 Patent Expirations and Generic Entry.

[2] Zhanel, G. G., et al. (2018). Tigecycline: A review of its use in the treatment of complicated infections. Clinical Therapeutics, 40(11), 1819-1834.

[3] Liu, P., et al. (2019). Pharmacokinetic interactions between rifampin and tigecycline: A systematic review. Journal of Pharmaceutical Sciences, 108(11), 3493-3504.

[4] Janssen Pharmaceuticals. (2023). Tigecycline - 2023 Package Insert.

Sources:

1. DrugPatentWatch.com: https://drugpatentwatch.com/
2. Zhanel, G. G. et al. (2018): https://www.sciencedirect.com/science/article/pii/S0149291718301022
3. Liu, P. et al. (2019): https://www.sciencedirect.com/science/article/pii/S0022354918301436
4. Janssen Pharmaceuticals: https://www.janssen.com/